Levonordefrin

Identification

Name
Levonordefrin
Accession Number
DB06707
Description

Levonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 183.2044
Monoisotopic: 183.089543287
Chemical Formula
C9H13NO3
Synonyms
  • (-)-cobefrin
  • alpha-Methylnoradrenaline
  • Corbadrina
  • Corbadrine
  • Corbadrinum
  • L-alpha-methylnoradrenaline
  • L-Nordefrin
  • Levonordefrin
  • Neo-cobefrin
External IDs
  • BA 2818
  • BA-2818

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication

Used as a topical nasal decongestant and vasoconstrictor in dentistry.

Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Levonordefrin is a sympathomimetic amine used as a vasoconstrictor in local anesthetic solutions. It has pharmacologic activity similar to that of Epinephrine but it is more stable than Epinephrine. In equal concentrations, Levonordefrin is less potent than Epinephrine in raising blood pressure, and as a vasoconstrictor.

Mechanism of action

It is designed to mimic the molecular shape of adrenaline. It binds to alpha-adrenergic receptors in the nasal mucosa. Here it can, therefore, cause vasoconstriction.

TargetActionsOrganism
AAlpha-2 adrenergic receptors
agonist
Humans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololThe therapeutic efficacy of Acebutolol can be increased when used in combination with Levonordefrin.
AceclofenacThe risk or severity of hypertension can be increased when Levonordefrin is combined with Aceclofenac.
AcemetacinThe risk or severity of hypertension can be increased when Levonordefrin is combined with Acemetacin.
AcetazolamideThe risk or severity of Cardiac Arrhythmia can be increased when Levonordefrin is combined with Acetazolamide.
AcetyldigitoxinThe risk or severity of Cardiac Arrhythmia can be increased when Levonordefrin is combined with Acetyldigitoxin.
Acetylsalicylic acidThe risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Levonordefrin.
AclidiniumThe risk or severity of Tachycardia can be increased when Levonordefrin is combined with Aclidinium.
AcrivastineThe therapeutic efficacy of Levonordefrin can be increased when used in combination with Acrivastine.
AdenosineThe risk or severity of Tachycardia can be increased when Adenosine is combined with Levonordefrin.
AlclofenacThe risk or severity of hypertension can be increased when Levonordefrin is combined with Alclofenac.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
No interactions found.

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
International/Other Brands
Neo-Cobefrin / Nordefrin
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
2% Polocaine Dental With Levonordefrin 1:20,000Levonordefrin (0.05 mg) + Mepivacaine hydrochloride (20 mg)SolutionInfiltrationDentsply Pharmaceutical1990-12-312011-08-04Canada flag
Carbocaine 2% With Neo-cobefrinLevonordefrin (0.05 mg) + Mepivacaine hydrochloride (20 mg)SolutionInfiltrationKodak Canada Inc.2005-04-222008-07-14Canada flag
Carbocaine 2% With Neo-cobefrinLevonordefrin (0.05 mg) + Mepivacaine hydrochloride (20 mg)SolutionInfiltrationCarestream Health Inc.2006-09-012018-09-06Canada flag
Carbocaine 2% With Neo-cobefrinLevonordefrin (0.05 mg) + Mepivacaine hydrochloride (20 mg)SolutionInfiltrationNovocol Inc.2019-07-30Not applicableCanada flag
Carbocaine with Neo-CobefrinLevonordefrin (0.05 mg/1mL) + Mepivacaine hydrochloride (20 mg/1mL)Injection, solutionSubcutaneousCaresteam Health, Inc.2011-01-01Not applicableUS flag
Carbocaine with Neo-CobefrinLevonordefrin (0.05 mg/1mL) + Mepivacaine hydrochloride (30 mg/1mL)Injection, solutionSubcutaneousSeptodont, Inc.2018-11-19Not applicableUS flag
Isocaine HCl Inj 2%Levonordefrin (0.05 mg) + Mepivacaine hydrochloride (20 mg)SolutionInfiltrationNovocol Inc.1977-12-31Not applicableCanada flag
Isocaine with LevonordefrinLevonordefrin (0.05 mg/1mL) + Mepivacaine hydrochloride (20 mg/1mL)Injection, solutionSubcutaneousNovocol Pharmaceutical of Canada Inc.2006-04-14Not applicableUS flag
Mepivacaine Hydrochloride and LevonordefrinLevonordefrin (0.05 mg/1mL) + Mepivacaine hydrochloride (20 mg/1mL)Injection, solutionSubcutaneousDarby Dental Supply Llc2011-01-14Not applicableUS flag
Mepivacaine Hydrochloride with LevonordefrinLevonordefrin (0.05 mg/1mL) + Mepivacaine hydrochloride (20 mg/1mL)Injection, solutionSubcutaneousHenry Schein Inc.2011-01-012016-05-24US flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenylpropanes. These are organic compounds containing a phenylpropane moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylpropanes
Direct Parent
Phenylpropanes
Alternative Parents
Catechols / Aralkylamines / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Secondary alcohols / 1,2-aminoalcohols / Organopnictogen compounds / Monoalkylamines / Hydrocarbon derivatives / Aromatic alcohols
Substituents
1,2-aminoalcohol / 1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / Alcohol / Amine / Aralkylamine / Aromatic alcohol / Aromatic homomonocyclic compound / Catechol / Hydrocarbon derivative
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
catecholamine (CHEBI:10304)

Chemical Identifiers

UNII
R81X549E70
CAS number
829-74-3
InChI Key
GEFQWZLICWMTKF-CDUCUWFYSA-N
InChI
InChI=1S/C9H13NO3/c1-5(10)9(13)6-2-3-7(11)8(12)4-6/h2-5,9,11-13H,10H2,1H3/t5-,9-/m0/s1
IUPAC Name
4-[(1R,2S)-2-amino-1-hydroxypropyl]benzene-1,2-diol
SMILES
C[C@H](N)[C@H](O)C1=CC(O)=C(O)C=C1

References

General References
Not Available
Human Metabolome Database
HMDB0015652
KEGG Drug
D02388
KEGG Compound
C11768
PubChem Compound
164739
PubChem Substance
99443259
ChemSpider
144416
BindingDB
50223426
RxNav
132889
ChEBI
10304
ChEMBL
CHEMBL677
ZINC
ZINC000000034157
PharmGKB
PA165958380
Guide to Pharmacology
GtP Drug Page
Wikipedia
Levonordefrin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Not Yet RecruitingTreatmentLocal anesthesia therapy1
Not AvailableUnknown StatusTreatmentEdema / Pain / Trismus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
InjectionSubcutaneous
InjectionDental
SolutionInfiltration
Injection, solutionSubcutaneous
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility14.6 mg/mLALOGPS
logP-0.77ALOGPS
logP-0.39ChemAxon
logS-1.1ALOGPS
pKa (Strongest Acidic)9.63ChemAxon
pKa (Strongest Basic)8.96ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area86.71 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity48.87 m3·mol-1ChemAxon
Polarizability18.81 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9908
Blood Brain Barrier-0.9476
Caco-2 permeable-0.5196
P-glycoprotein substrateNon-substrate0.6652
P-glycoprotein inhibitor INon-inhibitor0.9818
P-glycoprotein inhibitor IINon-inhibitor0.9946
Renal organic cation transporterNon-inhibitor0.9341
CYP450 2C9 substrateNon-substrate0.7936
CYP450 2D6 substrateNon-substrate0.7668
CYP450 3A4 substrateNon-substrate0.7456
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9466
CYP450 2D6 inhibitorNon-inhibitor0.9789
CYP450 2C19 inhibitorNon-inhibitor0.9294
CYP450 3A4 inhibitorNon-inhibitor0.9229
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8329
Ames testAMES toxic0.6857
CarcinogenicityNon-carcinogens0.8948
BiodegradationNot ready biodegradable0.7553
Rat acute toxicity2.0594 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9705
hERG inhibition (predictor II)Non-inhibitor0.9117
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Kind
Protein group
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...

Components:
References
  1. de Andrade CA, de Andrade GM, De Paula PM, De Luca LA Jr, Menani JV: Involvement of central alpha1-adrenoceptors on renal responses to central moxonidine and alpha-methylnoradrenaline. Eur J Pharmacol. 2009 Apr 1;607(1-3):60-7. [PubMed:19326476]

Drug created on May 16, 2010 01:00 / Updated on June 12, 2020 16:52